Bristol-Myers Squibb Company (BMY)
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
The Magnificent 7 Blue-Chip Dividend Stocks to Buy in 2025 and Hold Forever
Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 High-Yield Dividend Stocks to Buy Early in 2025
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their combination of above-average dividend yields and proven business models.
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
US FDA approves injectable form of Bristol Myers' Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
The European Commission approves Bristol Myers' Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new oncology registrational trials added in past year, as the management seeks to deliver new growth opportunities in the face of upcoming patent cliff. These developments also lend strength to BMY's Growth portfolio outperformance by +20% YoY, with the growth-to-legacy portfolio ratio increasingly skewed to the former at 48.7%.
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has promising new drugs like Cobenfy to offset potential revenue declines. Recent quarterly results show solid revenue growth, though earnings per share have declined, and management has raised revenue guidance for the fiscal year.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session.
